Supplementary Table S4 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma

Supplementary Table S4:
Molecular features of patient-derived LMS models used in these studies (three LMS cells lines and one LMS PDX), including clinical features of LMS tumors from Dana-Farber/Brigham and Women’s Hospital from which they were derived

补充表 S4：本研究中使用的患者来源的 LMS 模型（包括三个 LMS 细胞系和一个 LMS PDX）的分子特征，以及源于达纳-法伯/布里格姆和妇女医院（Dana-Farber/Brigham and Women’s Hospital）的 LMS 肿瘤的临床特征（其中所述肿瘤是这些模型的来源）